XML 59 R42.htm IDEA: XBRL DOCUMENT v3.8.0.1
Interim Consolidated Financial Information (Unaudited) (Tables)
 12 Months Ended
Dec. 31, 2017
Interim Consolidated Financial Information (Unaudited)  
Schedule of Interim Consolidated Financial Information

Note 17. Interim Consolidated Financial Information (Unaudited)

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Fiscal 2017 Quarter Ended

 

(in thousands, except per share data)

    

March 31,

    

June 30,

    

September 30,

    

December 31,

 

Revenues(1)

 

$

384,082

 

$

326,444

 

$

381,534

 

$

444,156

 

Net income (loss)

 

$

(187,083)

 

$

(12,484)

 

$

36,054

 

$

(149,629)

 

Basic net income (loss) per share

 

$

(0.96)

 

$

(0.06)

 

$

0.17

 

$

(0.71)

 

Diluted net income (loss) per share

 

$

(0.96)

 

$

(0.06)

 

$

0.17

 

$

(0.71)

 

Shares used in computation of basic net income (loss) per share

 

 

195,260

 

 

205,141

 

 

206,796

 

 

211,125

 

Shares used in computation of diluted net income (loss) per share

 

 

195,260

 

 

205,141

 

 

212,610

 

 

211,125

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Fiscal 2016 Quarter Ended

 

(in thousands, except per share data)

    

March 31,

    

June 30,

    

September 30,

    

December 31,

 

Revenues(2)

 

$

263,464

 

$

246,288

 

$

269,469

 

$

326,498

 

Net income

 

$

24,047

 

$

34,425

 

$

36,877

 

$

8,873

 

Basic net income per share

 

$

0.13

 

$

0.18

 

$

0.20

 

$

0.05

 

Diluted net income per share

 

$

0.12

 

$

0.18

 

$

0.19

 

$

0.05

 

Shares used in computation of basic net income per share

 

 

187,184

 

 

187,682

 

 

188,029

 

 

188,598

 

Shares used in computation of diluted net income per share

 

 

192,625

 

 

193,015

 

 

194,265

 

 

195,187

 

(1)

The quarters ended March 31, 2017, June 30, 2017, September 30, 2017 and December 31, 2017 include $264.8 million, $291.7 million, $322.0 million, and $321.8 million, respectively, of product revenues, net, relating to JAKAFI and ICLUSIG. The quarters ended March 31, 2017, June 30, 2017, September 30, 2017 and December 31, 2017 include $29.2 million, $34.8 million, $44.5 million and $52.3 million, respectively, of product royalty revenues related to the sale of JAKAVI and OLUMIANT outside the United States. In November 2009 and December 2009, we entered into collaborative research and license agreements with Novartis and Lilly, respectively. The quarters ended March 31, 2017, June 30, 2017, September 30, 2017 and December 31, 2017 include $90.0 million, $0.0 million, $15.0 million and $70.0 million, respectively, of milestone and contract revenues relating to these agreements.

(2)

The quarter ended March 31, 2016 includes $183.3 million of product revenues, net, relating to JAKAFI. The quarters ended June 30, 2016, September 30, 2016 and December 31, 2016 include $212.1 million, $236.6 million and $250.4 million, respectively, of product revenues, net, relating to JAKAFI and ICLUSIG. The quarters ended March 31, 2016, June 30, 2016, September 30, 2016 and December 31, 2016 include $21.9 million, $26.0 million, $29.6 million and $33.2 million, respectively, of product royalty revenues related to the sale of JAKAVI outside the United States. In November 2009 and December 2009, we entered into collaborative research and license agreements with Novartis and Lilly, respectively. The quarters ended March 31, 2016, June 30, 2016, September 30, 2016 and December 31, 2016 include $58.2 million, $8.2 million, $3.2 million and $42.9 million, respectively, of milestone and contract revenues relating to these agreements.